American Society of Hirudotherapy

Heparin-induced thrombosis with a normal platelet count

Case report published in Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine (2007)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportClinical LiteratureAlvarez et al. · Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2007

Abstract

Heparin is commonly used in the intensive care unit for preventing and treating thromboembolic disease. One of its more significant complications is heparin-induced thrombocytopenia (HIT), an immune-mediated disorder which can provoke an extreme prothrombotic state. We describe an unusual presentation of HIT, where thrombocytopenia was absent.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsComparative StudyJournal Article
Indexed MeSH termsAdultAnticoagulantsCalcitoninFemaleFollow-Up StudiesHeparinHirudinsHumansIntensive Care UnitsPartial Thromboplastin TimePlatelet CountProtein PrecursorsRecombinant ProteinsStrokeThrombocytopeniaThrombosisTime FactorsTomography, X-Ray Computed

Summary

This case report describes an unusual presentation of heparin-induced thrombocytopenia in which thrombocytopenia was absent despite the immune-mediated, extreme prothrombotic state that characterizes this complication of heparin therapy.

Why This Matters for Hirudotherapy

This case report describes an unusual presentation of heparin-induced thrombocytopenia (HIT) in the intensive care setting in which the characteristic drop in platelet count was absent, illustrating that this immune-mediated prothrombotic complication of heparin can occur without overt thrombocytopenia. It is relevant to the hirudotherapy story because HIT is the clinical problem that drove development of non-heparin anticoagulants, including the leech-derived direct thrombin inhibitor hirudin and its analogues, situating leech-secretome anticoagulants within the management of heparin-related complications. As a single case report it offers a clinical cautionary observation, not generalizable evidence, and the abstract makes no mention of leech therapy or hirudin.

Citation

Reference (Vancouver style)

Alvarez GF, Bihari D, Collins D. Heparin-induced thrombosis with a normal platelet count. Crit Care Resusc. 2007;9(1):51-53. PMID: 17352667

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 29, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.